nodes	percent_of_prediction	percent_of_DWPC	metapath
Treprostinil—P2RY12—prostate gland—urinary bladder cancer	0.0322	0.143	CbGeAlD
Treprostinil—PPARD—prostate gland—urinary bladder cancer	0.0268	0.119	CbGeAlD
Treprostinil—P2RY12—epithelium—urinary bladder cancer	0.0237	0.105	CbGeAlD
Treprostinil—PTGIR—prostate gland—urinary bladder cancer	0.0206	0.0911	CbGeAlD
Treprostinil—CYP2C9—urine—urinary bladder cancer	0.0205	0.0907	CbGeAlD
Treprostinil—PTGIR—epithelium—urinary bladder cancer	0.0151	0.067	CbGeAlD
Treprostinil—PPARD—female reproductive system—urinary bladder cancer	0.0146	0.0648	CbGeAlD
Treprostinil—PTGIR—smooth muscle tissue—urinary bladder cancer	0.0146	0.0645	CbGeAlD
Treprostinil—PTGIR—renal system—urinary bladder cancer	0.014	0.0621	CbGeAlD
Treprostinil—PPARD—vagina—urinary bladder cancer	0.0132	0.0586	CbGeAlD
Treprostinil—PTGIR—female reproductive system—urinary bladder cancer	0.0112	0.0497	CbGeAlD
Treprostinil—PPARD—lymph node—urinary bladder cancer	0.00855	0.0379	CbGeAlD
Treprostinil—PTGIR—lymph node—urinary bladder cancer	0.00657	0.0291	CbGeAlD
Treprostinil—CYP2C9—female reproductive system—urinary bladder cancer	0.00401	0.0178	CbGeAlD
Treprostinil—PPARD—Nuclear Receptors—ESR1—urinary bladder cancer	0.00312	0.0196	CbGpPWpGaD
Treprostinil—PPARD—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.00312	0.0196	CbGpPWpGaD
Treprostinil—PPARD—Nuclear Receptors—PPARG—urinary bladder cancer	0.00285	0.0179	CbGpPWpGaD
Treprostinil—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00266	0.0167	CbGpPWpGaD
Treprostinil—PPARD—Nuclear Receptor transcription pathway—ESR1—urinary bladder cancer	0.00247	0.0155	CbGpPWpGaD
Treprostinil—PTGIR—Prostaglandin Synthesis and Regulation—PTGS2—urinary bladder cancer	0.00247	0.0155	CbGpPWpGaD
Treprostinil—PPARD—Presenilin action in Notch and Wnt signaling—CREBBP—urinary bladder cancer	0.00235	0.0148	CbGpPWpGaD
Treprostinil—PPARD—Nuclear Receptor transcription pathway—PPARG—urinary bladder cancer	0.00225	0.0142	CbGpPWpGaD
Treprostinil—P2RY12—Signal amplification—SRC—urinary bladder cancer	0.00211	0.0133	CbGpPWpGaD
Treprostinil—PPARD—RXR and RAR heterodimerization with other nuclear receptor—TNF—urinary bladder cancer	0.00205	0.0129	CbGpPWpGaD
Treprostinil—CYP2C9—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00195	0.0123	CbGpPWpGaD
Treprostinil—PPARD—NRF2 pathway—NQO1—urinary bladder cancer	0.00177	0.0111	CbGpPWpGaD
Treprostinil—PPARD—Presenilin action in Notch and Wnt signaling—CCND1—urinary bladder cancer	0.00174	0.0109	CbGpPWpGaD
Treprostinil—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00169	0.0106	CbGpPWpGaD
Treprostinil—CYP2C9—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00167	0.0105	CbGpPWpGaD
Treprostinil—PTGIR—Thromboxane A2 receptor signaling—RHOA—urinary bladder cancer	0.00165	0.0104	CbGpPWpGaD
Treprostinil—PPARD—Wnt Signaling Pathway and Pluripotency—PLAU—urinary bladder cancer	0.00151	0.00947	CbGpPWpGaD
Treprostinil—PPARD—Adipogenesis—NCOR1—urinary bladder cancer	0.00149	0.00935	CbGpPWpGaD
Treprostinil—PPARD—NRF2 pathway—GSTP1—urinary bladder cancer	0.00147	0.00927	CbGpPWpGaD
Treprostinil—PPARD—Presenilin action in Notch and Wnt signaling—MYC—urinary bladder cancer	0.0014	0.00877	CbGpPWpGaD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.00139	0.00873	CbGpPWpGaD
Treprostinil—CYP2C9—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00137	0.00861	CbGpPWpGaD
Treprostinil—CYP2C9—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00136	0.00857	CbGpPWpGaD
Treprostinil—PPARD—NRF2 pathway—GSTM1—urinary bladder cancer	0.00136	0.00852	CbGpPWpGaD
Treprostinil—PPARD—Adipogenesis—FAS—urinary bladder cancer	0.00133	0.00838	CbGpPWpGaD
Treprostinil—PPARD—Wnt Signaling Pathway and Pluripotency—CREBBP—urinary bladder cancer	0.00124	0.00781	CbGpPWpGaD
Treprostinil—PTGIR—Thromboxane A2 receptor signaling—SRC—urinary bladder cancer	0.00121	0.00761	CbGpPWpGaD
Treprostinil—PPARD—Fatty acid, triacylglycerol, and ketone body metabolism—NCOR1—urinary bladder cancer	0.00115	0.00721	CbGpPWpGaD
Treprostinil—PPARD—Wnt Signaling Pathway and Pluripotency—RHOA—urinary bladder cancer	0.00112	0.00707	CbGpPWpGaD
Treprostinil—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00107	0.00174	CcSEcCtD
Treprostinil—Tachycardia—Cisplatin—urinary bladder cancer	0.00107	0.00174	CcSEcCtD
Treprostinil—PPARD—Adipogenesis—PPARG—urinary bladder cancer	0.00107	0.0067	CbGpPWpGaD
Treprostinil—Dehydration—Epirubicin—urinary bladder cancer	0.00106	0.00173	CcSEcCtD
Treprostinil—Insomnia—Gemcitabine—urinary bladder cancer	0.00106	0.00173	CcSEcCtD
Treprostinil—PTGIR—Thromboxane A2 receptor signaling—EGFR—urinary bladder cancer	0.00106	0.00667	CbGpPWpGaD
Treprostinil—Pain in extremity—Doxorubicin—urinary bladder cancer	0.00106	0.00172	CcSEcCtD
Treprostinil—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00106	0.00172	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00105	0.00171	CcSEcCtD
Treprostinil—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00105	0.0017	CcSEcCtD
Treprostinil—Chest pain—Etoposide—urinary bladder cancer	0.00105	0.0017	CcSEcCtD
Treprostinil—Insomnia—Fluorouracil—urinary bladder cancer	0.00105	0.0017	CcSEcCtD
Treprostinil—Anorexia—Cisplatin—urinary bladder cancer	0.00104	0.0017	CcSEcCtD
Treprostinil—Hypokalaemia—Epirubicin—urinary bladder cancer	0.00104	0.00169	CcSEcCtD
Treprostinil—CYP2C9—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.00104	0.00653	CbGpPWpGaD
Treprostinil—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00104	0.00169	CcSEcCtD
Treprostinil—Discomfort—Etoposide—urinary bladder cancer	0.00103	0.00168	CcSEcCtD
Treprostinil—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00103	0.00167	CcSEcCtD
Treprostinil—Hypotension—Cisplatin—urinary bladder cancer	0.00102	0.00166	CcSEcCtD
Treprostinil—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00102	0.00166	CcSEcCtD
Treprostinil—PPARD—Adipogenesis—RB1—urinary bladder cancer	0.00102	0.00641	CbGpPWpGaD
Treprostinil—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00102	0.00165	CcSEcCtD
Treprostinil—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.00101	0.00165	CcSEcCtD
Treprostinil—Fatigue—Gemcitabine—urinary bladder cancer	0.00101	0.00165	CcSEcCtD
Treprostinil—PPARD—Adipogenesis—IGF1—urinary bladder cancer	0.00101	0.00636	CbGpPWpGaD
Treprostinil—Pain—Gemcitabine—urinary bladder cancer	0.00101	0.00163	CcSEcCtD
Treprostinil—Decreased appetite—Fluorouracil—urinary bladder cancer	0.001	0.00163	CcSEcCtD
Treprostinil—Asthenia—Thiotepa—urinary bladder cancer	0.001	0.00163	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000998	0.00162	CcSEcCtD
Treprostinil—Infection—Etoposide—urinary bladder cancer	0.000997	0.00162	CcSEcCtD
Treprostinil—Influenza—Epirubicin—urinary bladder cancer	0.00099	0.00161	CcSEcCtD
Treprostinil—Pruritus—Thiotepa—urinary bladder cancer	0.000989	0.00161	CcSEcCtD
Treprostinil—Pain—Fluorouracil—urinary bladder cancer	0.000988	0.00161	CcSEcCtD
Treprostinil—Dehydration—Doxorubicin—urinary bladder cancer	0.000985	0.0016	CcSEcCtD
Treprostinil—Paraesthesia—Cisplatin—urinary bladder cancer	0.000984	0.0016	CcSEcCtD
Treprostinil—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000983	0.0016	CcSEcCtD
Treprostinil—Tachycardia—Etoposide—urinary bladder cancer	0.00098	0.00159	CcSEcCtD
Treprostinil—Dyspnoea—Cisplatin—urinary bladder cancer	0.000977	0.00159	CcSEcCtD
Treprostinil—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000969	0.00157	CcSEcCtD
Treprostinil—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000964	0.00157	CcSEcCtD
Treprostinil—Anorexia—Etoposide—urinary bladder cancer	0.000957	0.00156	CcSEcCtD
Treprostinil—Diarrhoea—Thiotepa—urinary bladder cancer	0.000956	0.00155	CcSEcCtD
Treprostinil—Decreased appetite—Cisplatin—urinary bladder cancer	0.000953	0.00155	CcSEcCtD
Treprostinil—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000953	0.00155	CcSEcCtD
Treprostinil—Bronchitis—Epirubicin—urinary bladder cancer	0.000952	0.00155	CcSEcCtD
Treprostinil—Pneumonia—Methotrexate—urinary bladder cancer	0.000948	0.00154	CcSEcCtD
Treprostinil—Depression—Methotrexate—urinary bladder cancer	0.00094	0.00153	CcSEcCtD
Treprostinil—Hypotension—Etoposide—urinary bladder cancer	0.000938	0.00152	CcSEcCtD
Treprostinil—Pain—Cisplatin—urinary bladder cancer	0.000937	0.00152	CcSEcCtD
Treprostinil—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	0.000932	0.00586	CbGpPWpGaD
Treprostinil—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000929	0.00151	CcSEcCtD
Treprostinil—Dizziness—Thiotepa—urinary bladder cancer	0.000924	0.0015	CcSEcCtD
Treprostinil—PPARD—Wnt Signaling Pathway and Pluripotency—CCND1—urinary bladder cancer	0.00092	0.00578	CbGpPWpGaD
Treprostinil—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000919	0.00578	CbGpPWpGaD
Treprostinil—Influenza—Doxorubicin—urinary bladder cancer	0.000916	0.00149	CcSEcCtD
Treprostinil—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000914	0.00149	CcSEcCtD
Treprostinil—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000903	0.00147	CcSEcCtD
Treprostinil—Paraesthesia—Etoposide—urinary bladder cancer	0.000901	0.00147	CcSEcCtD
Treprostinil—Haematuria—Methotrexate—urinary bladder cancer	0.000899	0.00146	CcSEcCtD
Treprostinil—Dyspnoea—Etoposide—urinary bladder cancer	0.000895	0.00145	CcSEcCtD
Treprostinil—Epistaxis—Methotrexate—urinary bladder cancer	0.000889	0.00145	CcSEcCtD
Treprostinil—Vomiting—Thiotepa—urinary bladder cancer	0.000889	0.00144	CcSEcCtD
Treprostinil—Pneumonia—Epirubicin—urinary bladder cancer	0.000887	0.00144	CcSEcCtD
Treprostinil—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	0.000883	0.00555	CbGpPWpGaD
Treprostinil—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	0.000883	0.00555	CbGpPWpGaD
Treprostinil—Rash—Thiotepa—urinary bladder cancer	0.000881	0.00143	CcSEcCtD
Treprostinil—Bronchitis—Doxorubicin—urinary bladder cancer	0.000881	0.00143	CcSEcCtD
Treprostinil—Dermatitis—Thiotepa—urinary bladder cancer	0.00088	0.00143	CcSEcCtD
Treprostinil—Headache—Thiotepa—urinary bladder cancer	0.000876	0.00142	CcSEcCtD
Treprostinil—Decreased appetite—Etoposide—urinary bladder cancer	0.000873	0.00142	CcSEcCtD
Treprostinil—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000871	0.00548	CbGpPWpGaD
Treprostinil—Body temperature increased—Cisplatin—urinary bladder cancer	0.000866	0.00141	CcSEcCtD
Treprostinil—Fatigue—Etoposide—urinary bladder cancer	0.000866	0.00141	CcSEcCtD
Treprostinil—Pain—Etoposide—urinary bladder cancer	0.000858	0.0014	CcSEcCtD
Treprostinil—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000858	0.00139	CcSEcCtD
Treprostinil—Haemoglobin—Methotrexate—urinary bladder cancer	0.000851	0.00138	CcSEcCtD
Treprostinil—PPARD—Wnt Signaling Pathway and Pluripotency—EP300—urinary bladder cancer	0.000847	0.00532	CbGpPWpGaD
Treprostinil—Haemorrhage—Methotrexate—urinary bladder cancer	0.000846	0.00138	CcSEcCtD
Treprostinil—Asthenia—Gemcitabine—urinary bladder cancer	0.000844	0.00137	CcSEcCtD
Treprostinil—Haematuria—Epirubicin—urinary bladder cancer	0.000841	0.00137	CcSEcCtD
Treprostinil—Pharyngitis—Methotrexate—urinary bladder cancer	0.00084	0.00137	CcSEcCtD
Treprostinil—Epistaxis—Epirubicin—urinary bladder cancer	0.000832	0.00135	CcSEcCtD
Treprostinil—Pruritus—Gemcitabine—urinary bladder cancer	0.000832	0.00135	CcSEcCtD
Treprostinil—Nausea—Thiotepa—urinary bladder cancer	0.00083	0.00135	CcSEcCtD
Treprostinil—Sinusitis—Epirubicin—urinary bladder cancer	0.000828	0.00135	CcSEcCtD
Treprostinil—Feeling abnormal—Etoposide—urinary bladder cancer	0.000827	0.00134	CcSEcCtD
Treprostinil—PPARD—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—urinary bladder cancer	0.000821	0.00516	CbGpPWpGaD
Treprostinil—Pneumonia—Doxorubicin—urinary bladder cancer	0.000821	0.00133	CcSEcCtD
Treprostinil—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000821	0.00133	CcSEcCtD
Treprostinil—Pruritus—Fluorouracil—urinary bladder cancer	0.000818	0.00133	CcSEcCtD
Treprostinil—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.000808	0.00508	CbGpPWpGaD
Treprostinil—Bradycardia—Epirubicin—urinary bladder cancer	0.000806	0.00131	CcSEcCtD
Treprostinil—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000804	0.00131	CcSEcCtD
Treprostinil—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000797	0.00501	CbGpPWpGaD
Treprostinil—Haemoglobin—Epirubicin—urinary bladder cancer	0.000796	0.00129	CcSEcCtD
Treprostinil—Rhinitis—Epirubicin—urinary bladder cancer	0.000794	0.00129	CcSEcCtD
Treprostinil—Body temperature increased—Etoposide—urinary bladder cancer	0.000794	0.00129	CcSEcCtD
Treprostinil—Abdominal pain—Etoposide—urinary bladder cancer	0.000794	0.00129	CcSEcCtD
Treprostinil—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000794	0.00129	CcSEcCtD
Treprostinil—PPARD—Metabolism—GSTZ1—urinary bladder cancer	0.000792	0.00498	CbGpPWpGaD
Treprostinil—Haemorrhage—Epirubicin—urinary bladder cancer	0.000792	0.00129	CcSEcCtD
Treprostinil—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000791	0.00129	CcSEcCtD
Treprostinil—PPARD—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—urinary bladder cancer	0.000789	0.00496	CbGpPWpGaD
Treprostinil—Asthenia—Cisplatin—urinary bladder cancer	0.000786	0.00128	CcSEcCtD
Treprostinil—Pharyngitis—Epirubicin—urinary bladder cancer	0.000786	0.00128	CcSEcCtD
Treprostinil—Oedema peripheral—Epirubicin—urinary bladder cancer	0.00078	0.00127	CcSEcCtD
Treprostinil—Haematuria—Doxorubicin—urinary bladder cancer	0.000778	0.00127	CcSEcCtD
Treprostinil—Epistaxis—Doxorubicin—urinary bladder cancer	0.00077	0.00125	CcSEcCtD
Treprostinil—Sinusitis—Doxorubicin—urinary bladder cancer	0.000766	0.00124	CcSEcCtD
Treprostinil—Dizziness—Fluorouracil—urinary bladder cancer	0.000764	0.00124	CcSEcCtD
Treprostinil—PPARD—Metabolism—GSTO2—urinary bladder cancer	0.000751	0.00472	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—NAT1—urinary bladder cancer	0.000751	0.00472	CbGpPWpGaD
Treprostinil—Diarrhoea—Cisplatin—urinary bladder cancer	0.00075	0.00122	CcSEcCtD
Treprostinil—Vomiting—Gemcitabine—urinary bladder cancer	0.000748	0.00121	CcSEcCtD
Treprostinil—Bradycardia—Doxorubicin—urinary bladder cancer	0.000746	0.00121	CcSEcCtD
Treprostinil—Rash—Gemcitabine—urinary bladder cancer	0.000741	0.0012	CcSEcCtD
Treprostinil—Dermatitis—Gemcitabine—urinary bladder cancer	0.000741	0.0012	CcSEcCtD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000739	0.00464	CbGpPWpGaD
Treprostinil—PPARD—Wnt Signaling Pathway and Pluripotency—MYC—urinary bladder cancer	0.000738	0.00464	CbGpPWpGaD
Treprostinil—Erythema—Methotrexate—urinary bladder cancer	0.000737	0.0012	CcSEcCtD
Treprostinil—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000737	0.0012	CcSEcCtD
Treprostinil—Headache—Gemcitabine—urinary bladder cancer	0.000737	0.0012	CcSEcCtD
Treprostinil—Flushing—Epirubicin—urinary bladder cancer	0.000735	0.00119	CcSEcCtD
Treprostinil—Vomiting—Fluorouracil—urinary bladder cancer	0.000735	0.00119	CcSEcCtD
Treprostinil—Rhinitis—Doxorubicin—urinary bladder cancer	0.000735	0.00119	CcSEcCtD
Treprostinil—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000733	0.00119	CcSEcCtD
Treprostinil—PPARD—Adipogenesis—CDKN1A—urinary bladder cancer	0.000733	0.00461	CbGpPWpGaD
Treprostinil—Rash—Fluorouracil—urinary bladder cancer	0.000729	0.00118	CcSEcCtD
Treprostinil—Dermatitis—Fluorouracil—urinary bladder cancer	0.000728	0.00118	CcSEcCtD
Treprostinil—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000727	0.00118	CcSEcCtD
Treprostinil—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.000727	0.00457	CbGpPWpGaD
Treprostinil—Headache—Fluorouracil—urinary bladder cancer	0.000724	0.00118	CcSEcCtD
Treprostinil—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000722	0.00117	CcSEcCtD
Treprostinil—Asthenia—Etoposide—urinary bladder cancer	0.00072	0.00117	CcSEcCtD
Treprostinil—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000717	0.00451	CbGpPWpGaD
Treprostinil—Back pain—Methotrexate—urinary bladder cancer	0.000713	0.00116	CcSEcCtD
Treprostinil—Pruritus—Etoposide—urinary bladder cancer	0.00071	0.00115	CcSEcCtD
Treprostinil—PPARD—Generic Transcription Pathway—ESR2—urinary bladder cancer	0.000703	0.00442	CbGpPWpGaD
Treprostinil—Nausea—Gemcitabine—urinary bladder cancer	0.000698	0.00113	CcSEcCtD
Treprostinil—Vomiting—Cisplatin—urinary bladder cancer	0.000697	0.00113	CcSEcCtD
Treprostinil—Rash—Cisplatin—urinary bladder cancer	0.000691	0.00112	CcSEcCtD
Treprostinil—Dermatitis—Cisplatin—urinary bladder cancer	0.00069	0.00112	CcSEcCtD
Treprostinil—Erythema—Epirubicin—urinary bladder cancer	0.00069	0.00112	CcSEcCtD
Treprostinil—PPARD—Metabolism—UGT2B7—urinary bladder cancer	0.000687	0.00432	CbGpPWpGaD
Treprostinil—Diarrhoea—Etoposide—urinary bladder cancer	0.000687	0.00112	CcSEcCtD
Treprostinil—Nausea—Fluorouracil—urinary bladder cancer	0.000687	0.00112	CcSEcCtD
Treprostinil—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000684	0.00111	CcSEcCtD
Treprostinil—Anaemia—Methotrexate—urinary bladder cancer	0.000681	0.00111	CcSEcCtD
Treprostinil—Flushing—Doxorubicin—urinary bladder cancer	0.00068	0.00111	CcSEcCtD
Treprostinil—Tension—Epirubicin—urinary bladder cancer	0.000677	0.0011	CcSEcCtD
Treprostinil—Nervousness—Epirubicin—urinary bladder cancer	0.00067	0.00109	CcSEcCtD
Treprostinil—Back pain—Epirubicin—urinary bladder cancer	0.000667	0.00108	CcSEcCtD
Treprostinil—Malaise—Methotrexate—urinary bladder cancer	0.000664	0.00108	CcSEcCtD
Treprostinil—Dizziness—Etoposide—urinary bladder cancer	0.000664	0.00108	CcSEcCtD
Treprostinil—Muscle spasms—Epirubicin—urinary bladder cancer	0.000663	0.00108	CcSEcCtD
Treprostinil—P2RY12—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	0.000654	0.00411	CbGpPWpGaD
Treprostinil—Nausea—Cisplatin—urinary bladder cancer	0.000651	0.00106	CcSEcCtD
Treprostinil—Cough—Methotrexate—urinary bladder cancer	0.000643	0.00104	CcSEcCtD
Treprostinil—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.00064	0.00104	CcSEcCtD
Treprostinil—Vomiting—Etoposide—urinary bladder cancer	0.000638	0.00104	CcSEcCtD
Treprostinil—Erythema—Doxorubicin—urinary bladder cancer	0.000638	0.00104	CcSEcCtD
Treprostinil—Anaemia—Epirubicin—urinary bladder cancer	0.000637	0.00104	CcSEcCtD
Treprostinil—Rash—Etoposide—urinary bladder cancer	0.000633	0.00103	CcSEcCtD
Treprostinil—Dermatitis—Etoposide—urinary bladder cancer	0.000632	0.00103	CcSEcCtD
Treprostinil—Headache—Etoposide—urinary bladder cancer	0.000629	0.00102	CcSEcCtD
Treprostinil—Chest pain—Methotrexate—urinary bladder cancer	0.000627	0.00102	CcSEcCtD
Treprostinil—Arthralgia—Methotrexate—urinary bladder cancer	0.000627	0.00102	CcSEcCtD
Treprostinil—Myalgia—Methotrexate—urinary bladder cancer	0.000627	0.00102	CcSEcCtD
Treprostinil—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000627	0.00394	CbGpPWpGaD
Treprostinil—Tension—Doxorubicin—urinary bladder cancer	0.000626	0.00102	CcSEcCtD
Treprostinil—Malaise—Epirubicin—urinary bladder cancer	0.000622	0.00101	CcSEcCtD
Treprostinil—Discomfort—Methotrexate—urinary bladder cancer	0.00062	0.00101	CcSEcCtD
Treprostinil—Nervousness—Doxorubicin—urinary bladder cancer	0.00062	0.00101	CcSEcCtD
Treprostinil—PPARD—Metabolism—CYP4B1—urinary bladder cancer	0.000619	0.00389	CbGpPWpGaD
Treprostinil—Syncope—Epirubicin—urinary bladder cancer	0.000618	0.001	CcSEcCtD
Treprostinil—Back pain—Doxorubicin—urinary bladder cancer	0.000617	0.001	CcSEcCtD
Treprostinil—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000615	0.00387	CbGpPWpGaD
Treprostinil—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000613	0.000997	CcSEcCtD
Treprostinil—Palpitations—Epirubicin—urinary bladder cancer	0.000609	0.00099	CcSEcCtD
Treprostinil—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000606	0.000985	CcSEcCtD
Treprostinil—PPARD—Wnt Signaling Pathway and Pluripotency—TP53—urinary bladder cancer	0.000606	0.00381	CbGpPWpGaD
Treprostinil—Cough—Epirubicin—urinary bladder cancer	0.000602	0.000978	CcSEcCtD
Treprostinil—P2RY12—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	0.0006	0.00377	CbGpPWpGaD
Treprostinil—Infection—Methotrexate—urinary bladder cancer	0.000597	0.000971	CcSEcCtD
Treprostinil—Nausea—Etoposide—urinary bladder cancer	0.000596	0.000969	CcSEcCtD
Treprostinil—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000592	0.000962	CcSEcCtD
Treprostinil—Anaemia—Doxorubicin—urinary bladder cancer	0.00059	0.000958	CcSEcCtD
Treprostinil—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000589	0.000957	CcSEcCtD
Treprostinil—Myalgia—Epirubicin—urinary bladder cancer	0.000587	0.000954	CcSEcCtD
Treprostinil—Arthralgia—Epirubicin—urinary bladder cancer	0.000587	0.000954	CcSEcCtD
Treprostinil—Chest pain—Epirubicin—urinary bladder cancer	0.000587	0.000954	CcSEcCtD
Treprostinil—Anxiety—Epirubicin—urinary bladder cancer	0.000585	0.000951	CcSEcCtD
Treprostinil—PPARD—Metabolism—SLC19A1—urinary bladder cancer	0.000584	0.00367	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—IFNA2—urinary bladder cancer	0.000584	0.00367	CbGpPWpGaD
Treprostinil—Discomfort—Epirubicin—urinary bladder cancer	0.00058	0.000943	CcSEcCtD
Treprostinil—PPARD—Ectoderm Differentiation—MYC—urinary bladder cancer	0.000579	0.00364	CbGpPWpGaD
Treprostinil—Malaise—Doxorubicin—urinary bladder cancer	0.000575	0.000935	CcSEcCtD
Treprostinil—Anorexia—Methotrexate—urinary bladder cancer	0.000573	0.000932	CcSEcCtD
Treprostinil—Syncope—Doxorubicin—urinary bladder cancer	0.000572	0.00093	CcSEcCtD
Treprostinil—PPARD—Metabolism—PRSS3—urinary bladder cancer	0.000569	0.00358	CbGpPWpGaD
Treprostinil—PPARD—Adipogenesis—TNF—urinary bladder cancer	0.000566	0.00356	CbGpPWpGaD
Treprostinil—Palpitations—Doxorubicin—urinary bladder cancer	0.000564	0.000916	CcSEcCtD
Treprostinil—Oedema—Epirubicin—urinary bladder cancer	0.000563	0.000915	CcSEcCtD
Treprostinil—Hypotension—Methotrexate—urinary bladder cancer	0.000562	0.000913	CcSEcCtD
Treprostinil—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000561	0.000911	CcSEcCtD
Treprostinil—Infection—Epirubicin—urinary bladder cancer	0.000559	0.000909	CcSEcCtD
Treprostinil—Cough—Doxorubicin—urinary bladder cancer	0.000557	0.000905	CcSEcCtD
Treprostinil—Shock—Epirubicin—urinary bladder cancer	0.000554	0.0009	CcSEcCtD
Treprostinil—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000551	0.000895	CcSEcCtD
Treprostinil—Tachycardia—Epirubicin—urinary bladder cancer	0.000549	0.000893	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000548	0.00089	CcSEcCtD
Treprostinil—Insomnia—Methotrexate—urinary bladder cancer	0.000544	0.000884	CcSEcCtD
Treprostinil—Arthralgia—Doxorubicin—urinary bladder cancer	0.000543	0.000883	CcSEcCtD
Treprostinil—Chest pain—Doxorubicin—urinary bladder cancer	0.000543	0.000883	CcSEcCtD
Treprostinil—Myalgia—Doxorubicin—urinary bladder cancer	0.000543	0.000883	CcSEcCtD
Treprostinil—PPARD—Generic Transcription Pathway—NCOR1—urinary bladder cancer	0.000543	0.00341	CbGpPWpGaD
Treprostinil—Anxiety—Doxorubicin—urinary bladder cancer	0.000541	0.00088	CcSEcCtD
Treprostinil—Paraesthesia—Methotrexate—urinary bladder cancer	0.00054	0.000878	CcSEcCtD
Treprostinil—PPARD—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	0.000537	0.00338	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—IFNA2—urinary bladder cancer	0.000537	0.00338	CbGpPWpGaD
Treprostinil—Discomfort—Doxorubicin—urinary bladder cancer	0.000537	0.000872	CcSEcCtD
Treprostinil—Anorexia—Epirubicin—urinary bladder cancer	0.000536	0.000872	CcSEcCtD
Treprostinil—Dyspnoea—Methotrexate—urinary bladder cancer	0.000536	0.000871	CcSEcCtD
Treprostinil—Dyspepsia—Methotrexate—urinary bladder cancer	0.000529	0.00086	CcSEcCtD
Treprostinil—Hypotension—Epirubicin—urinary bladder cancer	0.000526	0.000855	CcSEcCtD
Treprostinil—Decreased appetite—Methotrexate—urinary bladder cancer	0.000523	0.00085	CcSEcCtD
Treprostinil—Oedema—Doxorubicin—urinary bladder cancer	0.000521	0.000846	CcSEcCtD
Treprostinil—Fatigue—Methotrexate—urinary bladder cancer	0.000518	0.000843	CcSEcCtD
Treprostinil—Infection—Doxorubicin—urinary bladder cancer	0.000517	0.000841	CcSEcCtD
Treprostinil—Pain—Methotrexate—urinary bladder cancer	0.000514	0.000836	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000513	0.000833	CcSEcCtD
Treprostinil—Shock—Doxorubicin—urinary bladder cancer	0.000512	0.000833	CcSEcCtD
Treprostinil—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.00051	0.000829	CcSEcCtD
Treprostinil—Insomnia—Epirubicin—urinary bladder cancer	0.000509	0.000827	CcSEcCtD
Treprostinil—Tachycardia—Doxorubicin—urinary bladder cancer	0.000508	0.000826	CcSEcCtD
Treprostinil—Paraesthesia—Epirubicin—urinary bladder cancer	0.000505	0.000821	CcSEcCtD
Treprostinil—P2RY12—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	0.000503	0.00316	CbGpPWpGaD
Treprostinil—Dyspnoea—Epirubicin—urinary bladder cancer	0.000502	0.000815	CcSEcCtD
Treprostinil—P2RY12—G alpha (i) signalling events—CXCL8—urinary bladder cancer	0.000501	0.00315	CbGpPWpGaD
Treprostinil—Anorexia—Doxorubicin—urinary bladder cancer	0.000496	0.000807	CcSEcCtD
Treprostinil—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000496	0.000805	CcSEcCtD
Treprostinil—Dyspepsia—Epirubicin—urinary bladder cancer	0.000495	0.000805	CcSEcCtD
Treprostinil—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000492	0.000799	CcSEcCtD
Treprostinil—Decreased appetite—Epirubicin—urinary bladder cancer	0.000489	0.000795	CcSEcCtD
Treprostinil—Hypotension—Doxorubicin—urinary bladder cancer	0.000487	0.000791	CcSEcCtD
Treprostinil—Fatigue—Epirubicin—urinary bladder cancer	0.000485	0.000789	CcSEcCtD
Treprostinil—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000484	0.00304	CbGpPWpGaD
Treprostinil—Pain—Epirubicin—urinary bladder cancer	0.000481	0.000782	CcSEcCtD
Treprostinil—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000477	0.003	CbGpPWpGaD
Treprostinil—Body temperature increased—Methotrexate—urinary bladder cancer	0.000475	0.000773	CcSEcCtD
Treprostinil—Abdominal pain—Methotrexate—urinary bladder cancer	0.000475	0.000773	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000474	0.000771	CcSEcCtD
Treprostinil—Insomnia—Doxorubicin—urinary bladder cancer	0.000471	0.000765	CcSEcCtD
Treprostinil—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000468	0.00076	CcSEcCtD
Treprostinil—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000464	0.000754	CcSEcCtD
Treprostinil—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000464	0.000754	CcSEcCtD
Treprostinil—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.00046	0.000748	CcSEcCtD
Treprostinil—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000458	0.000745	CcSEcCtD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000456	0.00287	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—TYMP—urinary bladder cancer	0.000455	0.00286	CbGpPWpGaD
Treprostinil—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000453	0.000736	CcSEcCtD
Treprostinil—P2RY12—Signaling Pathways—HDAC4—urinary bladder cancer	0.000449	0.00283	CbGpPWpGaD
Treprostinil—Fatigue—Doxorubicin—urinary bladder cancer	0.000449	0.00073	CcSEcCtD
Treprostinil—Pain—Doxorubicin—urinary bladder cancer	0.000445	0.000724	CcSEcCtD
Treprostinil—Body temperature increased—Epirubicin—urinary bladder cancer	0.000445	0.000723	CcSEcCtD
Treprostinil—Abdominal pain—Epirubicin—urinary bladder cancer	0.000445	0.000723	CcSEcCtD
Treprostinil—P2RY12—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	0.000439	0.00276	CbGpPWpGaD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000437	0.00275	CbGpPWpGaD
Treprostinil—Asthenia—Methotrexate—urinary bladder cancer	0.000431	0.000701	CcSEcCtD
Treprostinil—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000429	0.000697	CcSEcCtD
Treprostinil—PPARD—Generic Transcription Pathway—ESR1—urinary bladder cancer	0.000427	0.00268	CbGpPWpGaD
Treprostinil—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000426	0.000692	CcSEcCtD
Treprostinil—Pruritus—Methotrexate—urinary bladder cancer	0.000425	0.000691	CcSEcCtD
Treprostinil—P2RY12—Hemostasis—PLAU—urinary bladder cancer	0.000414	0.0026	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—HDAC4—urinary bladder cancer	0.000414	0.0026	CbGpPWpGaD
Treprostinil—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000412	0.000669	CcSEcCtD
Treprostinil—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000412	0.000669	CcSEcCtD
Treprostinil—PPARD—Metabolism—NAT2—urinary bladder cancer	0.000412	0.00259	CbGpPWpGaD
Treprostinil—Diarrhoea—Methotrexate—urinary bladder cancer	0.000411	0.000669	CcSEcCtD
Treprostinil—Asthenia—Epirubicin—urinary bladder cancer	0.000404	0.000656	CcSEcCtD
Treprostinil—P2RY12—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000398	0.0025	CbGpPWpGaD
Treprostinil—Pruritus—Epirubicin—urinary bladder cancer	0.000398	0.000647	CcSEcCtD
Treprostinil—Dizziness—Methotrexate—urinary bladder cancer	0.000398	0.000646	CcSEcCtD
Treprostinil—PPARD—Generic Transcription Pathway—PPARG—urinary bladder cancer	0.000389	0.00245	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—SMC1A—urinary bladder cancer	0.000389	0.00244	CbGpPWpGaD
Treprostinil—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000387	0.00243	CbGpPWpGaD
Treprostinil—Diarrhoea—Epirubicin—urinary bladder cancer	0.000385	0.000626	CcSEcCtD
Treprostinil—Vomiting—Methotrexate—urinary bladder cancer	0.000382	0.000621	CcSEcCtD
Treprostinil—PTGIR—Hemostasis—PLAU—urinary bladder cancer	0.000381	0.0024	CbGpPWpGaD
Treprostinil—Rash—Methotrexate—urinary bladder cancer	0.000379	0.000616	CcSEcCtD
Treprostinil—Dermatitis—Methotrexate—urinary bladder cancer	0.000379	0.000616	CcSEcCtD
Treprostinil—Headache—Methotrexate—urinary bladder cancer	0.000377	0.000612	CcSEcCtD
Treprostinil—P2RY12—Signaling Pathways—GLI1—urinary bladder cancer	0.000377	0.00237	CbGpPWpGaD
Treprostinil—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000375	0.00236	CbGpPWpGaD
Treprostinil—PPARD—Generic Transcription Pathway—CREBBP—urinary bladder cancer	0.000374	0.00235	CbGpPWpGaD
Treprostinil—Asthenia—Doxorubicin—urinary bladder cancer	0.000374	0.000607	CcSEcCtD
Treprostinil—Dizziness—Epirubicin—urinary bladder cancer	0.000372	0.000605	CcSEcCtD
Treprostinil—Pruritus—Doxorubicin—urinary bladder cancer	0.000368	0.000599	CcSEcCtD
Treprostinil—PTGIR—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000367	0.0023	CbGpPWpGaD
Treprostinil—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000362	0.00228	CbGpPWpGaD
Treprostinil—Vomiting—Epirubicin—urinary bladder cancer	0.000358	0.000581	CcSEcCtD
Treprostinil—Nausea—Methotrexate—urinary bladder cancer	0.000357	0.00058	CcSEcCtD
Treprostinil—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000356	0.000579	CcSEcCtD
Treprostinil—PPARD—Metabolism—RRM2—urinary bladder cancer	0.000355	0.00223	CbGpPWpGaD
Treprostinil—Rash—Epirubicin—urinary bladder cancer	0.000355	0.000577	CcSEcCtD
Treprostinil—Dermatitis—Epirubicin—urinary bladder cancer	0.000354	0.000576	CcSEcCtD
Treprostinil—Headache—Epirubicin—urinary bladder cancer	0.000353	0.000573	CcSEcCtD
Treprostinil—PTGIR—Signaling Pathways—GLI1—urinary bladder cancer	0.000347	0.00218	CbGpPWpGaD
Treprostinil—Dizziness—Doxorubicin—urinary bladder cancer	0.000344	0.00056	CcSEcCtD
Treprostinil—P2RY12—Hemostasis—CREBBP—urinary bladder cancer	0.000342	0.00215	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—ESR2—urinary bladder cancer	0.000339	0.00213	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—IGF1—urinary bladder cancer	0.000337	0.00212	CbGpPWpGaD
Treprostinil—Nausea—Epirubicin—urinary bladder cancer	0.000334	0.000543	CcSEcCtD
Treprostinil—Vomiting—Doxorubicin—urinary bladder cancer	0.000331	0.000538	CcSEcCtD
Treprostinil—PPARD—Metabolism—HPGDS—urinary bladder cancer	0.000329	0.00207	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—ENO2—urinary bladder cancer	0.000329	0.00207	CbGpPWpGaD
Treprostinil—Rash—Doxorubicin—urinary bladder cancer	0.000328	0.000534	CcSEcCtD
Treprostinil—Dermatitis—Doxorubicin—urinary bladder cancer	0.000328	0.000533	CcSEcCtD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000327	0.00206	CbGpPWpGaD
Treprostinil—Headache—Doxorubicin—urinary bladder cancer	0.000326	0.00053	CcSEcCtD
Treprostinil—PPARD—Metabolism—GSTT1—urinary bladder cancer	0.000319	0.00201	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—CREBBP—urinary bladder cancer	0.000314	0.00198	CbGpPWpGaD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000314	0.00198	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—IGF1—urinary bladder cancer	0.00031	0.00195	CbGpPWpGaD
Treprostinil—Nausea—Doxorubicin—urinary bladder cancer	0.000309	0.000503	CcSEcCtD
Treprostinil—P2RY12—Hemostasis—RHOA—urinary bladder cancer	0.000309	0.00194	CbGpPWpGaD
Treprostinil—P2RY12—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000303	0.00191	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—RHOA—urinary bladder cancer	0.000284	0.00179	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000279	0.00176	CbGpPWpGaD
Treprostinil—PTGIR—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000279	0.00176	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—NQO1—urinary bladder cancer	0.000265	0.00167	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—NCOR1—urinary bladder cancer	0.000261	0.00164	CbGpPWpGaD
Treprostinil—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.00026	0.00164	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—IL2—urinary bladder cancer	0.000259	0.00163	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—RBX1—urinary bladder cancer	0.000258	0.00162	CbGpPWpGaD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000257	0.00162	CbGpPWpGaD
Treprostinil—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000257	0.00161	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—ERCC2—urinary bladder cancer	0.000246	0.00155	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—TSC1—urinary bladder cancer	0.000243	0.00153	CbGpPWpGaD
Treprostinil—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000239	0.0015	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—IL2—urinary bladder cancer	0.000239	0.0015	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—RBX1—urinary bladder cancer	0.000238	0.00149	CbGpPWpGaD
Treprostinil—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000236	0.00148	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—EP300—urinary bladder cancer	0.000233	0.00146	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—JAG1—urinary bladder cancer	0.000231	0.00145	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—SRC—urinary bladder cancer	0.000226	0.00142	CbGpPWpGaD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.000224	0.00141	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—TSC1—urinary bladder cancer	0.000223	0.0014	CbGpPWpGaD
Treprostinil—PPARD—Generic Transcription Pathway—MYC—urinary bladder cancer	0.000222	0.00139	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—GSTP1—urinary bladder cancer	0.000221	0.00139	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—EP300—urinary bladder cancer	0.000214	0.00135	CbGpPWpGaD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000214	0.00135	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—JAG1—urinary bladder cancer	0.000213	0.00134	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—SRC—urinary bladder cancer	0.000208	0.00131	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—TYMS—urinary bladder cancer	0.000206	0.00129	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—ESR1—urinary bladder cancer	0.000205	0.00129	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—NCOR1—urinary bladder cancer	0.000203	0.00128	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—GSTM1—urinary bladder cancer	0.000203	0.00128	CbGpPWpGaD
Treprostinil—P2RY12—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000195	0.00123	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—GPX1—urinary bladder cancer	0.000195	0.00122	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—ERCC2—urinary bladder cancer	0.000191	0.0012	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—PPARG—urinary bladder cancer	0.000187	0.00118	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—KRAS—urinary bladder cancer	0.000187	0.00118	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—S100B—urinary bladder cancer	0.000187	0.00118	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—CREBBP—urinary bladder cancer	0.00018	0.00113	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—RHOA—urinary bladder cancer	0.00018	0.00113	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—MTHFR—urinary bladder cancer	0.00018	0.00113	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—RHOA—urinary bladder cancer	0.000177	0.00111	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—KRAS—urinary bladder cancer	0.000172	0.00108	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—S100B—urinary bladder cancer	0.000172	0.00108	CbGpPWpGaD
Treprostinil—P2RY12—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000171	0.00108	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—NCOR1—urinary bladder cancer	0.000168	0.00106	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—TP53—urinary bladder cancer	0.000167	0.00105	CbGpPWpGaD
Treprostinil—P2RY12—GPCR downstream signaling—IL2—urinary bladder cancer	0.000164	0.00103	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—RHOA—urinary bladder cancer	0.000163	0.00103	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	0.000159	0.001	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—HRAS—urinary bladder cancer	0.000159	0.001	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000158	0.000992	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000156	0.000979	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—NCOR1—urinary bladder cancer	0.000155	0.000973	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—TP53—urinary bladder cancer	0.000153	0.000963	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	0.000151	0.00095	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NAT1—urinary bladder cancer	0.000151	0.00095	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—IL2—urinary bladder cancer	0.000151	0.000948	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—IL2—urinary bladder cancer	0.000149	0.000935	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000149	0.000934	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—TERT—urinary bladder cancer	0.000148	0.000932	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—HRAS—urinary bladder cancer	0.000147	0.000921	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PPARG—urinary bladder cancer	0.000146	0.000916	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000143	0.000901	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—CREBBP—urinary bladder cancer	0.00014	0.00088	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	0.000138	0.000868	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—IL2—urinary bladder cancer	0.000137	0.000861	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—TERT—urinary bladder cancer	0.000136	0.000858	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—FGFR3—urinary bladder cancer	0.000136	0.000855	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—ESR1—urinary bladder cancer	0.000132	0.000831	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—FGFR3—urinary bladder cancer	0.000125	0.000787	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	0.000124	0.000782	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—ESR1—urinary bladder cancer	0.000122	0.000764	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	0.000117	0.000738	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CREBBP—urinary bladder cancer	0.000116	0.000728	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PTGS2—urinary bladder cancer	0.000115	0.00072	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	0.000114	0.00072	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—IGF1—urinary bladder cancer	0.000114	0.000719	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—EGFR—urinary bladder cancer	0.000114	0.000715	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—KRAS—urinary bladder cancer	0.000108	0.000676	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—MYC—urinary bladder cancer	0.000107	0.000671	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CREBBP—urinary bladder cancer	0.000107	0.00067	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—IGF1—urinary bladder cancer	0.000105	0.000662	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—RHOA—urinary bladder cancer	0.000105	0.000659	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—EGFR—urinary bladder cancer	0.000105	0.000658	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PTEN—urinary bladder cancer	9.99e-05	0.000628	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—KRAS—urinary bladder cancer	9.89e-05	0.000622	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—ERBB2—urinary bladder cancer	9.7e-05	0.00061	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—RHOA—urinary bladder cancer	9.64e-05	0.000606	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—EP300—urinary bladder cancer	9.53e-05	0.000599	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CXCL8—urinary bladder cancer	9.2e-05	0.000578	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	9.18e-05	0.000577	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—TYMP—urinary bladder cancer	9.15e-05	0.000575	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—HRAS—urinary bladder cancer	9.14e-05	0.000574	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—ERBB2—urinary bladder cancer	8.93e-05	0.000561	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—IL2—urinary bladder cancer	8.79e-05	0.000553	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	8.79e-05	0.000553	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CCND1—urinary bladder cancer	8.57e-05	0.000539	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CXCL8—urinary bladder cancer	8.46e-05	0.000532	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—HRAS—urinary bladder cancer	8.41e-05	0.000529	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—MMP9—urinary bladder cancer	8.32e-05	0.000523	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CDKN1A—urinary bladder cancer	8.29e-05	0.000521	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NAT2—urinary bladder cancer	8.28e-05	0.00052	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PTEN—urinary bladder cancer	8.27e-05	0.00052	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—IL2—urinary bladder cancer	8.09e-05	0.000509	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—EP300—urinary bladder cancer	7.89e-05	0.000496	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CCND1—urinary bladder cancer	7.89e-05	0.000496	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—SRC—urinary bladder cancer	7.67e-05	0.000482	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—MMP9—urinary bladder cancer	7.66e-05	0.000481	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CDKN1A—urinary bladder cancer	7.63e-05	0.00048	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PTEN—urinary bladder cancer	7.61e-05	0.000478	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—EP300—urinary bladder cancer	7.26e-05	0.000456	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—RRM2—urinary bladder cancer	7.14e-05	0.000449	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—SRC—urinary bladder cancer	7.06e-05	0.000444	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—MYC—urinary bladder cancer	6.87e-05	0.000432	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—EGFR—urinary bladder cancer	6.72e-05	0.000423	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	6.62e-05	0.000416	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ENO2—urinary bladder cancer	6.62e-05	0.000416	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.58e-05	0.000413	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	6.42e-05	0.000403	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—KRAS—urinary bladder cancer	6.35e-05	0.000399	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—MYC—urinary bladder cancer	6.33e-05	0.000398	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	6.32e-05	0.000397	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—EGFR—urinary bladder cancer	6.19e-05	0.000389	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—KRAS—urinary bladder cancer	5.84e-05	0.000367	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—TP53—urinary bladder cancer	5.64e-05	0.000355	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—HRAS—urinary bladder cancer	5.4e-05	0.000339	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NQO1—urinary bladder cancer	5.33e-05	0.000335	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—TP53—urinary bladder cancer	5.19e-05	0.000327	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.17e-05	0.000325	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—HRAS—urinary bladder cancer	4.97e-05	0.000312	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.51e-05	0.000284	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	4.45e-05	0.00028	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.3e-05	0.000271	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—TYMS—urinary bladder cancer	4.14e-05	0.00026	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	4.09e-05	0.000257	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	4.09e-05	0.000257	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GPX1—urinary bladder cancer	3.91e-05	0.000246	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	3.84e-05	0.000242	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	3.61e-05	0.000227	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PPARG—urinary bladder cancer	2.93e-05	0.000184	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	2.81e-05	0.000177	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	2.3e-05	0.000145	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PTEN—urinary bladder cancer	2.01e-05	0.000126	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.92e-05	0.00012	CbGpPWpGaD
